Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Exploring metabolic dysfunction in chronic kidney disease.

Slee AD.

Nutr Metab (Lond). 2012 Apr 26;9(1):36. doi: 10.1186/1743-7075-9-36.

2.

Pharmacological strategies for kidney function preservation: are there differences by ethnicity?

Lakkis J, Weir MR.

Adv Ren Replace Ther. 2004 Jan;11(1):24-40. Review.

PMID:
14730536
3.

SP 04-1 THE ROLE OF NATRIURETIC PEPTIDES IN THE PATHOGENESIS OF CARDIOVASCULAR DISEASES.

Kobalava Z.

J Hypertens. 2016 Sep;34 Suppl 1 - ISH 2016 Abstract Book:e377.

PMID:
27754186
4.

SSA 04-3 LEPTIN/ADIPONECTIN IN CARDIOMETABOLIC DISEASE.

Lopez-Jaramillo P.

J Hypertens. 2016 Sep;34 Suppl 1 - ISH 2016 Abstract Book:e7.

PMID:
27753812
5.

Cardiovascular disease and its relationship with chronic kidney disease.

Liu M, Li XC, Lu L, Cao Y, Sun RR, Chen S, Zhang PY.

Eur Rev Med Pharmacol Sci. 2014 Oct;18(19):2918-26. Review.

6.

Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease: effects of angiotensin II blockade.

de Vinuesa SG, Goicoechea M, Kanter J, Puerta M, Cachofeiro V, Lahera V, Gómez-Campderá F, Luño J.

J Am Soc Nephrol. 2006 Dec;17(12 Suppl 3):S206-12.

7.

[Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].

Cases Amenós A, Goicoechea Diezhandiño M, de Alvaro Moreno F.

Nefrologia. 2008;28 Suppl 3:39-48. Spanish.

8.

SY 05-2 PROGRESSION OF HYPERTENSIVE HEART DISEASE: NEW THERAPEUTIC APPROACH.

Horiuchi M.

J Hypertens. 2016 Sep;34 Suppl 1 - ISH 2016 Abstract Book:e18.

PMID:
27753836
9.

Orexigenic and anorexigenic mechanisms in the control of nutrition in chronic kidney disease.

Mak RH, Cheung W, Cone RD, Marks DL.

Pediatr Nephrol. 2005 Mar;20(3):427-31. Epub 2005 Jan 21. Review.

PMID:
15662537
10.

Renin-angiotensin-aldosterone system intervention in the cardiometabolic syndrome and cardio-renal protection.

Whaley-Connell A, Pavey BS, Chaudhary K, Saab G, Sowers JR.

Ther Adv Cardiovasc Dis. 2007 Oct;1(1):27-35. doi: 10.1177/1753944707082697. Review.

PMID:
19124393
12.

Protein Nutrition and Malnutrition in CKD and ESRD.

Zha Y, Qian Q.

Nutrients. 2017 Feb 27;9(3). pii: E208. doi: 10.3390/nu9030208. Review.

13.

Effects of aliskiren on blood pressure and the predictive biomarkers for cardiovascular disease in hemodialysis-dependent chronic kidney disease patients with hypertension.

Morishita Y, Hanawa S, Chinda J, Iimura O, Tsunematsu S, Kusano E.

Hypertens Res. 2011 Mar;34(3):308-13. doi: 10.1038/hr.2010.238. Epub 2010 Dec 2.

PMID:
21124333
15.
16.

Aldosterone: role in the cardiometabolic syndrome and resistant hypertension.

Whaley-Connell A, Johnson MS, Sowers JR.

Prog Cardiovasc Dis. 2010 Mar-Apr;52(5):401-9. doi: 10.1016/j.pcad.2009.12.004. Review.

17.

Salt, aldosterone, and insulin resistance: impact on the cardiovascular system.

Lastra G, Dhuper S, Johnson MS, Sowers JR.

Nat Rev Cardiol. 2010 Oct;7(10):577-84. doi: 10.1038/nrcardio.2010.123. Epub 2010 Aug 10. Review.

PMID:
20697411
18.

The role of aldosterone in cardiovascular disease in people with diabetes and hypertension: an update.

Lastra-Gonzalez G, Manrique-Acevedo C, Sowers JR.

Curr Diab Rep. 2008 Jun;8(3):203-7. Review.

PMID:
18625117
19.

The role of novel biomarkers of cardiovascular disease in chronic kidney disease: focus on adiponectin and leptin.

Kaisar OM, Johnson DW, Prins JB, Isbel N.

Curr Cardiol Rev. 2008 Nov;4(4):287-92. doi: 10.2174/157340308786349516.

20.

BR 04-1MANAGEMENT OF TREATMENT-RESISTANT HYPERTENSION.

Webb DJ.

J Hypertens. 2016 Sep;34 Suppl 1 - ISH 2016 Abstract Book:e198.

PMID:
27754015

Supplemental Content

Support Center